NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
3,850 trialsNCT02482376 2026-03-17
Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer
Duke University
Phase 2 Active not recruiting
NCT02818920 2026-03-17
TOP 1501
Duke University
Phase 2 Completed
NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
NCT02648282 2026-03-13
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03475186 2026-03-13
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Wake Forest University Health Sciences
Phase 2 Completed
NCT04301778 2026-03-13
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04676360 2026-03-13
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT03386357 2026-03-12
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Erlangen-Nürnberg Medical School
Phase 2 Terminated
NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT05744375 2026-03-12
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT00492050 2026-03-11
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01266642 2026-03-11
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02712723 2026-03-11
FELINE
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03313804 2026-03-11
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
Phase 2 Completed
NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated
NCT04151667 2026-03-11
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
NCT03446157 2026-03-10
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03523702 2026-03-10
SPRINT
Albert Einstein College of Medicine
Phase 2 Completed
NCT03477539 2026-03-09
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT03808077 2026-03-09
The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03999749 2026-03-09
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Active not recruiting
NCT04030455 2026-03-09
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01616875 2026-03-06
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT02047474 2026-03-06
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Yale University
Phase 2 Completed
NCT03322267 2026-03-06
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
National Taiwan University Hospital
Phase 2 Completed
NCT03361306 2026-03-06
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Wake Forest University Health Sciences
Phase 2 Completed
NCT04231851 2026-03-06
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
University of California, Irvine
Phase 2 Active not recruiting
NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
NCT02946996 2026-03-05
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Medical University of South Carolina
Phase 2 Terminated
NCT03506373 2026-03-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
Phase 2 Terminated
NCT03941730 2026-03-05
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT00186992 2026-03-04
Radiation Therapy to Treat Musculoskeletal Tumors
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT02286726 2026-03-04
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03849651 2026-03-04
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT04288687 2026-03-04
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01560416 2026-03-03
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03519412 2026-03-03
ARETHUSA
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Completed
NCT04091750 2026-03-03
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
Georgetown University
Phase 2 Active not recruiting
NCT01919086 2026-03-02
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02031250 2026-03-02
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03211988 2026-03-02
Entinostat Neuroendocrine (NE) Tumor
Columbia University
Phase 2 Terminated
NCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03686488 2026-03-02
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT05148078 2026-03-02
Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT04268277 2026-02-27
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Phase 2 Terminated